vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Toast, Inc. (TOST). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.6B, roughly 1.7× Toast, Inc.). Toast, Inc. runs the higher net margin — 6.2% vs -3.7%, a 9.9% gap on every dollar of revenue. On growth, Toast, Inc. posted the faster year-over-year revenue change (22.0% vs 9.3%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $178.0M). Over the past eight quarters, Toast, Inc.'s revenue compounded faster (23.3% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Toast, Inc. is an American cloud-based restaurant management software company based in Boston, Massachusetts. The company provides an all-in-one point of sale (POS) system built on the Android operating system.
BHC vs TOST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.6B |
| Net Profit | $-103.0M | $101.0M |
| Gross Margin | — | 25.9% |
| Operating Margin | 17.0% | 5.2% |
| Net Margin | -3.7% | 6.2% |
| Revenue YoY | 9.3% | 22.0% |
| Net Profit YoY | -205.1% | 215.6% |
| EPS (diluted) | $-0.30 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.6B | ||
| Q3 25 | $2.7B | $1.6B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.3B | $1.3B | ||
| Q4 24 | $2.6B | $1.3B | ||
| Q3 24 | $2.5B | $1.3B | ||
| Q2 24 | $2.4B | $1.2B | ||
| Q1 24 | $2.2B | $1.1B |
| Q4 25 | $-103.0M | $101.0M | ||
| Q3 25 | $179.0M | $105.0M | ||
| Q2 25 | $148.0M | $80.0M | ||
| Q1 25 | $-58.0M | $56.0M | ||
| Q4 24 | $98.0M | $32.0M | ||
| Q3 24 | $-85.0M | $56.0M | ||
| Q2 24 | $10.0M | $14.0M | ||
| Q1 24 | $-64.0M | $-83.0M |
| Q4 25 | — | 25.9% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | — | 25.3% | ||
| Q1 25 | — | 25.9% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 23.2% |
| Q4 25 | 17.0% | 5.2% | ||
| Q3 25 | 23.1% | 5.1% | ||
| Q2 25 | 17.5% | 5.2% | ||
| Q1 25 | 12.2% | 3.2% | ||
| Q4 24 | 21.8% | 2.5% | ||
| Q3 24 | 12.7% | 2.6% | ||
| Q2 24 | 16.2% | 0.4% | ||
| Q1 24 | 13.1% | -5.2% |
| Q4 25 | -3.7% | 6.2% | ||
| Q3 25 | 6.7% | 6.4% | ||
| Q2 25 | 5.8% | 5.2% | ||
| Q1 25 | -2.6% | 4.2% | ||
| Q4 24 | 3.8% | 2.4% | ||
| Q3 24 | -3.4% | 4.3% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | -3.0% | -7.7% |
| Q4 25 | $-0.30 | $0.18 | ||
| Q3 25 | $0.48 | $0.16 | ||
| Q2 25 | $0.40 | $0.13 | ||
| Q1 25 | $-0.16 | $0.09 | ||
| Q4 24 | $0.24 | $0.09 | ||
| Q3 24 | $-0.23 | $0.07 | ||
| Q2 24 | $0.03 | $0.02 | ||
| Q1 24 | $-0.17 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $1.4B |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $2.1B |
| Total Assets | $26.4B | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.2B | $903.0M | ||
| Q3 24 | $719.0M | $761.0M | ||
| Q2 24 | $595.0M | $691.0M | ||
| Q1 24 | $733.0M | $578.0M |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | $2.1B | ||
| Q3 25 | $-565.0M | $2.0B | ||
| Q2 25 | $-764.0M | $1.8B | ||
| Q1 25 | $-1.2B | $1.7B | ||
| Q4 24 | $-1.3B | $1.5B | ||
| Q3 24 | $-1.2B | $1.4B | ||
| Q2 24 | $-1.2B | $1.3B | ||
| Q1 24 | $-1.1B | $1.2B |
| Q4 25 | $26.4B | $3.1B | ||
| Q3 25 | $26.8B | $3.0B | ||
| Q2 25 | $27.3B | $2.8B | ||
| Q1 25 | $26.4B | $2.6B | ||
| Q4 24 | $26.5B | $2.4B | ||
| Q3 24 | $26.5B | $2.2B | ||
| Q2 24 | $26.5B | $2.2B | ||
| Q1 24 | $26.9B | $2.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $194.0M |
| Free Cash FlowOCF − Capex | $403.0M | $178.0M |
| FCF MarginFCF / Revenue | 14.4% | 10.9% |
| Capex IntensityCapex / Revenue | 3.3% | 1.0% |
| Cash ConversionOCF / Net Profit | — | 1.92× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $608.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $194.0M | ||
| Q3 25 | $405.0M | $165.0M | ||
| Q2 25 | $289.0M | $223.0M | ||
| Q1 25 | $211.0M | $79.0M | ||
| Q4 24 | $601.0M | $147.0M | ||
| Q3 24 | $405.0M | $109.0M | ||
| Q2 24 | $380.0M | $124.0M | ||
| Q1 24 | $211.0M | $-20.0M |
| Q4 25 | $403.0M | $178.0M | ||
| Q3 25 | $314.0M | $153.0M | ||
| Q2 25 | $190.0M | $208.0M | ||
| Q1 25 | $96.0M | $69.0M | ||
| Q4 24 | $495.0M | $134.0M | ||
| Q3 24 | $334.0M | $97.0M | ||
| Q2 24 | $302.0M | $108.0M | ||
| Q1 24 | $129.0M | $-33.0M |
| Q4 25 | 14.4% | 10.9% | ||
| Q3 25 | 11.7% | 9.4% | ||
| Q2 25 | 7.5% | 13.4% | ||
| Q1 25 | 4.2% | 5.2% | ||
| Q4 24 | 19.3% | 10.0% | ||
| Q3 24 | 13.3% | 7.4% | ||
| Q2 24 | 12.6% | 8.7% | ||
| Q1 24 | 6.0% | -3.1% |
| Q4 25 | 3.3% | 1.0% | ||
| Q3 25 | 3.4% | 0.7% | ||
| Q2 25 | 3.9% | 1.0% | ||
| Q1 25 | 5.1% | 0.7% | ||
| Q4 24 | 4.1% | 1.0% | ||
| Q3 24 | 2.8% | 0.9% | ||
| Q2 24 | 3.2% | 1.3% | ||
| Q1 24 | 3.8% | 1.2% |
| Q4 25 | — | 1.92× | ||
| Q3 25 | 2.26× | 1.57× | ||
| Q2 25 | 1.95× | 2.79× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | 6.13× | 4.59× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | 38.00× | 8.86× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
TOST
| Technology Service | $1.3B | 82% |
| License | $256.0M | 16% |
| Product And Professional Services | $43.0M | 3% |
